China’s Sinovac (NASDAQ: SVA) has announced a partnership with Universidad de Antioquia of Colombia (UdeA) to collaborate on the construction of a vaccine research and development (R&D) center. The collaboration aims to enhance technical exchanges on vaccines and novel therapies, as well as to conduct basic research and translational studies in immunology, microbiology, and other related fields. The partnership also focuses on the development of vaccines and novel products targeting infectious diseases. No financial details were disclosed.
Objective of the Partnership
The primary goal of this collaboration is to strengthen technical exchanges and research capabilities in vaccine development and novel therapies. By working together, Sinovac and Universidad de Antioquia aim to advance basic research and translational studies in immunology and microbiology, ultimately leading to the development of new vaccines and innovative products targeting infectious diseases.
Sinovac’s Presence in Latin America
Sinovac’s SARS-CoV-2 vaccine, CoronaVac, has been approved in multiple locations across Latin America, including Colombia. The country has received over 27 million doses of CoronaVac from Sinovac, highlighting the company’s significant contribution to the region’s vaccination efforts.
Future Outlook
This partnership underscores Sinovac’s commitment to expanding its global presence and enhancing its research capabilities through collaboration with leading academic institutions. By working closely with Universidad de Antioquia, Sinovac aims to drive innovation in vaccine development and contribute to the global fight against infectious diseases.-Fineline Info & Tech
